BioAtla (BCAB) Non-Current Assets (2020 - 2026)
BioAtla's (BCAB) quarterly Non-Current Assets came in at $5.2 million in Q2 2026, down 19.46% on a YoY basis from $6.5 million in Q2 2025, and down 4.11% quarter-over-quarter from $5.5 million in Q1 2026.
Analysis
BioAtla (BCAB) Non-Current Assets (2020 - 2026) Analysis & Trends
BioAtla (BCAB) has reported Non-Current Assets for 7 consecutive years, with $5.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non-Current Assets fell 19.46% year-over-year to $5.2 million; the trailing twelve-month figure through Jun 2026 stood at $22.8 million (up 124.86% YoY), and the FY2025 full-year result was $5.8 million, up 388.66% from the prior year.
- Non-Current Assets eased to $5.2 million in Q2 2026 per BCAB's latest filing, from $5.5 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $6.6 million in Q1 2022 and bottomed at $753000.0 in Q1 2025.
- Historically, Non-Current Assets has averaged $4.3 million across 5 years, with a median of $5.0 million in 2023.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets sank 72.84% in 2025, then surged 626.83% in 2026.
- Over 5 years, Non-Current Assets stood at $5.3 million in 2022, then slumped by 38.7% to $3.3 million in 2023, then tumbled by 63.41% to $1.2 million in 2024, then soared by 388.66% to $5.8 million in 2025, then retreated by 9.75% to $5.2 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $5.2 million, $5.5 million, and $5.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.24 Bn | 192.25 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 180.01 Bn | 176.83 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 131.33 Bn | 123.47 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 81.87 Bn | 73.87 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 60.27 Bn | 55.08 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 53.93 Bn | 48.79 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 33.17 Bn | 29.86 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.89 Bn | 30.60 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 29.12 Bn | 29.12 Bn | 1.16 Mn | 564.41 Mn |
| 10 | BioAtla | 2.33 Mn | 2.33 Mn | - | 5.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.25 Mn |
| Mar 31, 2026 | 5.47 Mn |
| Dec 31, 2025 | 5.82 Mn |
| Sep 30, 2025 | 6.24 Mn |
| Jun 30, 2025 | 6.52 Mn |
| Mar 31, 2025 | 753,000.00 |
| Dec 31, 2024 | 1.19 Mn |
| Sep 30, 2024 | 1.67 Mn |
| Jun 30, 2024 | 2.15 Mn |
| Mar 31, 2024 | 2.77 Mn |
| Dec 31, 2023 | 3.25 Mn |
| Sep 30, 2023 | 3.85 Mn |
| Jun 30, 2023 | 4.33 Mn |
| Mar 31, 2023 | 4.84 Mn |
| Dec 31, 2022 | 5.31 Mn |
| Sep 30, 2022 | 5.80 Mn |
| Jun 30, 2022 | 6.30 Mn |
| Mar 31, 2022 | 6.63 Mn |
| Dec 31, 2021 | 7.13 Mn |
| Sep 30, 2021 | 4.06 Mn |